Results 61 to 70 of about 663,256 (217)

Progression-free survival in the ICON8 trial – Authors' reply [PDF]

The Lancet, 2020
James, EC, McNeish, IA, Cook, AD, Kaplan, R, Clamp, AR   +4 more
openaire   +4 more sources

P2.07-07 Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors [PDF]

, 2023
Lei Deng, Changchuan Jiang, Stuthi Perimbeti, Grace K. Dy   +3 more
openalex   +1 more source

Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma

Cancer Imaging
Background To develop a magnetic resonance imaging (MRI)-based radiomics signature for evaluating the risk of soft tissue sarcoma (STS) disease progression.
Yuan Yu, Hongwei Guo, Meng Zhang, Feng Hou, Shifeng Yang, Chencui Huang, Lisha Duan, Hexiang Wang   +7 more
doaj   +1 more source

Progression‐free survival as a surrogate marker of overall survival [PDF]

Cancer, 2011
The use of progression‐free survival as a surrogate marker of efficacy in cancer treatment has been the subject of much discussion in recent years. However, it should not be considered a surrogate marker for overall survival.
openaire   +2 more sources

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression‐free survival among patients with low‐grade neuroendocrine tumors [PDF]

, 2007
Jun Zhang, Zhiliang Jia, Qiang Li, Liwei Wang, Asif Rashid, Zhenggang Zhu, Douglas B. Evans, Jean‐Nicolas Vauthey, Keping Xie, James C. Yao   +9 more
openalex   +1 more source

18F-FDG PET/CT radiomics signature and clinical parameters predict progression-free survival in breast cancer patients: A preliminary study [PDF]

, 2023
Xiaojun Xu, Xun Sun, Ling Ma, Huangqi Zhang, Wenbin Ji, Xiaotian Xia, Xiaoli Lan   +6 more
openalex   +1 more source

Peritumoral infiltration of CD3 lymphocytes makes a difference in prostate cancer [PDF]

Vojnosanitetski Pregled
Background/Aim. Prostate cancer (PC) is the second most common malignancy in men, and the fifth leading cause of cancer death. The most important prognostic parameters are tumor, node, and metastasis (TNM) status, initial prostate-specific antigen (PSA),
Vještica Milka, Trivunić-Dajko Sandra, Babić Božana, Jungić Saša, Berendika Jelena   +4 more
doaj   +1 more source

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology
PURPOSE Despite major increases in the longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC), most men still die of prostate cancer. Phase III trials assessing new therapies in mHSPC with overall survival (OS) as the primary end point will take approximately a decade to complete.
Susan Halabi, Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael A. Carducci, Matthew R. Smith, Michael J. Morris, Gwenaelle Gravis, David P. Dearnaley, Paul Verhagen, Takayuki Goto, Nick James, Marc E. Buyse, Jayne F. Tierney, Christopher Sweeney   +19 more
openaire   +3 more sources

Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

BMC Gastroenterology, 2019
Background Capecitabine plus bevacizumab (CAP-B) maintenance treatment after 6 cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOXB) has demonstrated clinical activity and failure to compromise quality of life in patients with metastatic ...
Jinsong Su, Jiajie Lai, Ruikun Yang, Bo Xu, Ying Zhu, Mingdong Zhao, Chen Yang, Guanzhao Liang   +7 more
doaj   +1 more source

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan

Diabetes, Metabolic Syndrome and Obesity, 2021
Kaori Hisanaga,1 Hiroshi Uchino,1 Naoko Kakisu,1 Masahiko Miyagi,1 Fukumi Yoshikawa,1 Genki Sato,1 Kazutoshi Isobe,2 Kazuma Kishi,2 Sakae Homma,3 Takahisa Hirose1 1Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho ...
Hisanaga K, Uchino H, Kakisu N, Miyagi M, Yoshikawa F, Sato G, Isobe K, Kishi K, Homma S, Hirose T   +9 more
doaj